# EDGAR Filing Document

**Accession Number:** 0001641631
**File Stem:** 0001493152-26-006708
**Filing Date:** 2026-2
**Character Count:** 28213
**Document Hash:** d14b5cdcc10a54706ac10bdeab33c30e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-006708.hdr.sgml**: 20260213

**ACCESSION NUMBER**: 0001493152-26-006708

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260213

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260213

**DATE AS OF CHANGE**: 20260213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Beyond Air, Inc.
- **CENTRAL INDEX KEY:** 0001641631
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473812456
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38892
- **FILM NUMBER:** 26633048

**BUSINESS ADDRESS:**
- **STREET 1:** 900 STEWART AVENUE
- **STREET 2:** SUITE 301
- **CITY:** GARDEN CITY
- **STATE:** NY
- **ZIP:** 11530
- **BUSINESS PHONE:** 516-665-8200

**MAIL ADDRESS:**
- **STREET 1:** 900 STEWART AVENUE
- **STREET 2:** SUITE 301
- **CITY:** GARDEN CITY
- **STATE:** NY
- **ZIP:** 11530

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIT Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20170117

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KokiCare, Inc.
- **DATE OF NAME CHANGE:** 20150507

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): February 13, 2026**

**Beyond Air, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38892** | **47-3812456** |
| **(State or Other Jurisdiction**<br> **of Incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**900 Stewart Avenue, Suite 301**

**Garden City, NY 11530**

**(Address of Principal Executive Offices and Zip Code)**

**(516) 665-8200**

**Registrant's Telephone Number, Including Area Code**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, par value $.0001 per share** | **XAIR** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On February 13, 2026, Beyond Air, Inc. (the "Company") issued a press release announcing certain financial results for its third quarter ended December 31, 2025, and certain corporate updates. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information, including the exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended ("Securities Act"), except as shall be expressly set forth by specific reference in such filing.

**Item 7.01 Regulation FD Disclosure**

The information under Item 2.02 above is incorporated herein by reference.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The information in this Item 7.01 disclosure, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.**  | **Description** |
| 99.1 | [Press Release of Beyond Air, Inc., dated as of February 13, 2026.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BEYOND AIR, Inc.** | **BEYOND AIR, Inc.** |
| Date: February 13, 2026 | By: | */s/ Steven A. Lisi* |
|  | Name: | Steven A. Lisi |
|  | Title | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update**

 

*Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3*

 

*Maintain fiscal year 2026 revenue guidance of $8-10 million* 

 

*$22.3 million pro forma cash, cash equivalents, restricted cash and marketable securities, including net proceeds from recent PIPE transaction, expected to provide runway into calendar 2027* 

 

*Signed binding letter of intent for XTL Biopharmaceuticals to acquire 85% of Beyond Air's subsidiary NeuroNOS; Beyond Air to receive up to $32.5 million from the combination of upfront cash, development and commercial milestones and 19.99% equity ownership in XTL Biopharmaceuticals*

 

*Phase 1a data from UNO program in solid tumors to be presented at AACR Annual Meeting in April 2026*

 

*Conference call at 8:00 a.m. ET today, February 13<sup>th</sup>*

**Garden City, NY, February 13, 2026 *–*** Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced its financial results for the fiscal third quarter ended December 31, 2025, and provided a corporate update.

"We exceeded $2.0 million in quarterly revenue which marks an important milestone as we continue scaling our business and building awareness of the benefits our tankless NO system delivers in real-world settings," said Steve Lisi, Chief Executive Officer of Beyond Air. "Our commercial performance reflects steady momentum, with 21% sequential quarterly growth and a 105% increase over the same quarter last year. We will continue to grow our business with LungFit PH as we prepare for the FDA clearance of our second-generation LungFit PH system, which we expect to receive before the end of calendar 2026, subject to regulatory review. We believe the significant enhancements, including reduced weight and footprint, simplified operation, longer service interval, and full compatibility with both air and ground transport, will dramatically accelerate market share gains and position Beyond Air as a global leader in hospital-based NO delivery."

"We are excited that an abstract featuring Phase 1a data from Beyond Cancer's UNO program in solid tumors was selected to be presented at the AACR 2026 Annual Meeting in April. The team will present the latest exciting clinical data from this important trial," concluded Mr. Lisi.

The Company had a pro forma cash balance of approximately $22.3 million, which includes cash, cash equivalents, restricted cash and marketable securities of $17.8 million as of December 31, 2025, plus net proceeds of approximately $4.5 million from the Company's previously announced private placement that closed on January 14, 2026, and assumes no other changes to cash, cash equivalents, restricted cash and marketable securities since December 31, 2025.

**<u>Commercial Execution, Recent Highlights and Upcoming Milestones</u>**

● **LungFit® PH Commercial Execution** 

○ Revenue increased 105% to $2.2 million for the fiscal quarter ended December 31, 2025, compared to $1.1 million for the same period last year. Growth was driven by increased demand for LungFit PH in both the U.S. and international markets.

○ The Company completed its first sale of LungFit PH systems to a VA Medical Center during the fiscal third quarter of 2026, creating a potential pathway for future orders and broader adoption across the VA system. Engagement with VA centers provides access to the largest healthcare network in the U.S.

○ Expanded Global LungFit PH distribution network, including new agreements in Canada, Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing the total international coverage to 40 countries, representing a combined population of more than three billion people, nine times greater than the United States population.

● **Corporate Highlights** 

○ Appointed Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Mr. Moorhead brings more than 20 years of finance leadership experience across both public and private companies.

○ Announced that Board member Bob Carey will assume the role of Chairman of the Board, reflecting the Board's continued focus on strengthening governance and supporting the Company's next phase of commercial and strategic growth. Mr. Carey's experience and leadership are expected to provide valuable guidance as Beyond Air advances its regulatory, commercial, and strategic initiatives. Mr. Lisi will remain on the Board of Directors.

○ Strengthened the balance sheet with approximately $4.5 million in net proceeds from the private placement announced on January 14, 2026.

● **Pending Regulatory Milestones** 

○ Awaiting approval of the PMA supplement for the second-generation LungFit PH, which was submitted to U.S. FDA in June 2025.

○ International submissions for LungFit PH remain on track with local partners.

**Beyond Cancer - Solid Tumor Program –** clinical stage development of an intratumoral ultra-high concentration Nitric Oxide (UNO) technology as a gas delivery of NO at high concentrations to tumors to induce an immune response.

● **Clinical Development Execution** 

○ Phase 1a trial (monotherapy) - Part A of the trial evaluating UNO therapy in 10 subjects with advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid tumors at a dose of 25,000 ppm has been completed.

○ An abstract featuring data from the study was selected for presentation at the 2026 AACR Annual Meeting, which is taking place April 17-22, in San Diego, California.

○ Phase 1b trial (combination therapy) – Will assess the intratumoral administration of 25,000 ppm low volume (LV) Nitric Oxide (UNO) in subjects with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions, who have shown disease progression or prolonged stable disease (12 weeks) after receiving a single agent anti-PD-1 containing treatment.

**NeuroNOS –** On January 13, 2026, XTL Biopharmaceuticals Ltd. announced a binding agreement to acquire 85% of NeuroNOS Ltd. for consideration, under which Beyond Air, for its approximately 85% ownership, will receive 19.9% of XTL's issued share capital, $1.0 million in cash, and milestone-based contingent payments totaling up to $31.5 million.

Upon closing of the agreement, NeuroNOS will serve as XTL's flagship platform for autism and neuro-oncology therapeutics.

**Financial Results for the Fiscal Quarter Ended December 31, 2025**

Revenues for the fiscal quarter ended December 31, 2025 increased 105% to $2.2 million, compared with $1.1 million for the fiscal quarter ended December 31, 2024. Gross profit increased to $0.3 million for the quarter ended December 31, 2025, compared with a gross loss of $0.2 million for the quarter ended December 31, 2024. The increase in gross profit was primarily attributed to sales growth.

Research and development expenses for the fiscal quarter ended December 31, 2025 decreased 19% to $2.4 million compared with $3.0 million for the fiscal quarter ended December 31, 2024.

Selling, general and administrative expenses for the quarters ended December 31, 2025 and 2024 were $4.5 million and $7.7 million, respectively. The decrease of 42% or $3.2 million was primarily attributed to a reduction in employee-related costs.

Other expense for the quarter ended December 31, 2025 was $1.0 million compared with other expense of $2.4 million for the quarter ended December 31, 2024. The decrease in expense of $1.4 million was primarily attributed to the prior period loss associated with the extinguishment of debt.

Net loss attributed to common stockholders of Beyond Air, Inc. for the quarter ended December 31, 2025 was ($7.3) million or a loss of ($0.85) per share, basic and diluted, compared to a net loss attributed to common stockholders of Beyond Air, Inc. for the fiscal quarter ended December 31, 2024 of ($13.0) million or a loss of ($2.96) per share, basic and diluted.

Net cash burn, excluding inflows from financing activities, in the fiscal quarter ended December 31, 2025 was $4.3 million.

As of December 31, 2025, the Company reported cash, cash equivalents, restricted cash and marketable securities of $17.8 million. Subsequent to the end of the fiscal third quarter, the Company completed a private placement for net proceeds of $4.5 million. The Company believes this provides a cash runway into calendar year 2027.

Total long-term debt outstanding was $22.0 million as of December 31, 2025. The Company has $18.8 million remaining through an equity line of credit. The $12 million promissory note announced in November 2025 bears a 15% interest rate and matures 24 months from the issuance date, with no payments due during the first 12 months.

**Financial Guidance for Fiscal Year 2026**

The Company maintained its revenue guidance of $8-10 million for the fiscal year ending March 31, 2026.

**Conference Call & Webcast**

***<u>Friday, February 13<sup>th</sup> @ 8:00 AM ET</u>***

---

| | |
|:---|:---|
| Domestic: | 1-877-407-0784 |
| International: | 1-201-689-8560 |
| Conference ID: | 13758405 |
| Webcast: | A webcast of the live conference call can be accessed by visiting the Events section of the Company's website (<u>click here</u>) or directly (<u>click here</u>). An online replay will be available on the Company's website or via the direct link an hour after the call. |

---

**About Beyond Air<sup>®</sup>, Inc.**

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit <u>www.beyondair.net</u>.

**About LungFit \***

Beyond Air's LungFit is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.

LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

*\*Beyond Air's LungFit PH is approved for commercial use in the United States, European Union, and many other countries around the world. Beyond Air's other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.*

**About PPHN** 

Persistent pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth. It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1,000 live births (0.4–6.8/1000 live births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilator support and other appropriate agents.

**About Beyond Cancer, Ltd.**

Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human study is underway in subjects with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models to inform additional treatment protocols. For more information, visit <u>www.beyondcancer.com</u>.

**Forward Looking Statements**

 

*This press release contains "forward-looking statements" concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words "appears," "expects," "plans," "anticipates," "believes" "expects," "intends," "looks," "projects," "goal," "assumes," "targets" and similar expressions and/or the use of future tense or conditional constructions (such as "will," "may," "could," "should" and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the "Risk Factors" section of Beyond Air's most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air's website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.*

**CONTACTS:**

**Investor Relations contacts**

Corey Davis, Ph.D.

LifeSci Advisors, LLC

<u>Cdavis@lifesciadvisors.com</u>

(212) 915-2577

**BEYOND AIR, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except share data)**

---

| | | |
|:---|:---|:---|
|  | **December 31, 2025** | **March 31, 2025** |
|  | (Unaudited) | |
| ASSETS |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $6643 | $4665 |
| &nbsp;&nbsp;&nbsp;Marketable securities | 5018 | 2252 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 6187 | 231 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 1151 | 710 |
| &nbsp;&nbsp;&nbsp;Inventory, net | 1761 | 2417 |
| &nbsp;&nbsp;&nbsp;Other current assets and prepaid expenses | 4804 | 5743 |
| Total current assets | 25564 | 16018 |
| &nbsp;&nbsp;&nbsp;Licensed right to use technology | 1069 | 1222 |
| &nbsp;&nbsp;&nbsp;Right-of-use lease assets | 1464 | 1706 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 8502 | 11013 |
| &nbsp;&nbsp;&nbsp;Other assets | 175 | 103 |
| TOTAL ASSETS | $36774 | $30062 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $2202 | $1950 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 2401 | 2045 |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities, current portion | 386 | 396 |
| &nbsp;&nbsp;&nbsp;Loans payable, current portion | - | 609 |
| Total current liabilities | 4989 | 5000 |
| Operating lease liabilities, net | 1231 | 1486 |
| Long-term debt, net | 21974 | 9197 |
| Warrant liability | 2 | 38 |
| Derivative liability | 292 | - |
| Total liabilities | 28488 | 15721 |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Common Stock, $0.0001 par value per share: 500,000,000 shares authorized, 8,404,354 and 4,128,539 shares issued and outstanding as of December 31, 2025 and March 31, 2025, respectively (1) | 1 |  |
| &nbsp;&nbsp;&nbsp;Treasury stock | (25) | (25) |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 317314 | 299990 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (309289) | (286322) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | 110 | (60) |
| &nbsp;&nbsp;&nbsp;Total stockholders' equity attributable to Beyond Air, Inc | 8111 | 13583 |
| &nbsp;&nbsp;&nbsp;Non-controlling interest | 175 | 758 |
| &nbsp;&nbsp;&nbsp;Total stockholders' equity | 8286 | 14341 |
| &nbsp;&nbsp;&nbsp;TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $36774 | $30062 |

---

(1) Prior period results have
 been adjusted to reflect the one-for-twenty stock split in July 2025.

**BEYOND AIR, INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(amounts in thousands, except share and per share data)** 

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenues | $2194 | $1072 | $5772 | $2553 |
| Cost of revenues | 1894 | 1287 | 5614 | 4184 |
| Gross profit (loss) | 300 | (215) | 158 | (1631) |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | 2429 | 3005 | 7965 | 13599 |
| &nbsp;&nbsp;&nbsp;Selling, general and administrative | 4467 | 7732 | 14067 | 22133 |
| Total operating expenses | 6896 | 10737 | 22032 | 35732 |
| Loss from operations | (6596) | (10952) | (21874) | (37363) |
| Other income/(expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Dividend/investment income | 102 | 126 | 189 | 637 |
| &nbsp;&nbsp;&nbsp;Interest and finance expense | (1088) | (549) | (2275) | (2439) |
| &nbsp;&nbsp;&nbsp;Change in fair value of warrant liability | 20 | 4 | 36 | 219 |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | 483 |  | 483 | 1314 |
| &nbsp;&nbsp;&nbsp;Foreign exchange gain/(loss) | (30) | 46 | (89) | (26) |
| &nbsp;&nbsp;&nbsp;Loss on extinguishment of debt |  | (1910) |  | (2534) |
| &nbsp;&nbsp;&nbsp;Loss on disposal of fixed assets | (359) | (62) | (416) | (233) |
| &nbsp;&nbsp;&nbsp;Other income/(expense) | (162) | (37) | (20) | 11 |
| Total other income/(expense) | (1034) | (2381) | (2092) | (3052) |
| Loss before income taxes | (7630) | (13333) | (23966) | (40416) |
| Provision for income taxes | - | - | - | - |
| Net loss | $(7630) | $(13333) | $(23966) | $(40416) |
| Less: net loss attributable to non-controlling interest | (294) | (300) | (999) | (1825) |
| Net loss attributable to Beyond Air, Inc. | $(7336) | $(13032) | $(22967) | $(38591) |
| Other comprehensive income/(loss), net of tax |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustment | 25 | (61) | 170 | (37) |
| Comprehensive loss attributable to Beyond Air, Inc. | $(7311) | $(13093) | $(22797) | $(38628) |
| Net basic and diluted loss per share attributable to Beyond Air, Inc. (1) | $(0.85) | $(2.96) | $(3.44) | $(12.77) |
| Weighted average number of shares of common stock outstanding, basic and diluted (1) | 8616860 | 4403726 | 6668782 | 3020861 |

---

(1) Prior period results have been adjusted to reflect the
 one-for-twenty stock split in July 2025.